<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01063023</url>
  </required_header>
  <id_info>
    <org_study_id>AI447-019</org_study_id>
    <nct_id>NCT01063023</nct_id>
  </id_info>
  <brief_title>Drug Interaction Oral Contraceptive Pill (OCP)</brief_title>
  <official_title>Effect of BMS-650032 on the Pharmacokinetics of a Combined Oral Contraceptive Containing Ethinyl Estradiol and Norgestimate (Ortho Tri- Cyclen (R)) in Healthy Female Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the effects of BMS-650032 on Pharmacokinetics (PK) of ethinyl estradiol (EE) and
      norelgestromin (NGMN) in healthy female subjects
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">June 2010</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetics parameters for ethinyl estradiol (EE), norelgestromin (NGMN) and norgestrel (NG), AUC (TAU)</measure>
    <time_frame>24 hours of dosing</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the safety and tolerability of investigational drug and Ortho Tri-Cyclen® when administered</measure>
    <time_frame>Safety will be assessed through day 78</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To characterize the PK of norgestrel when Ortho Tri-Cylen® is administered alone and in combination</measure>
    <time_frame>PK assessments will be done on Day 49, 50, 77 and 78</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Hepatitis C Virus</condition>
  <arm_group>
    <arm_group_label>Arm A - Ortho Tri-Cyclen®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1 to 28 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B - Ortho Tri-Cyclen®</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>29 to 56 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm C - Ortho Tri-Cyclen® + BMS-650032</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ortho Tri-Cyclen®: 57 to 77 days
BMS-650032: 68 to 77 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ortho Tri-Cyclen®</intervention_name>
    <description>Tablets, Oral, 1 Tablet, once daily</description>
    <arm_group_label>Arm A - Ortho Tri-Cyclen®</arm_group_label>
    <arm_group_label>Arm B - Ortho Tri-Cyclen®</arm_group_label>
    <arm_group_label>Arm C - Ortho Tri-Cyclen® + BMS-650032</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-650032</intervention_name>
    <description>Tablets, Oral, 600 mg, BID</description>
    <arm_group_label>Arm C - Ortho Tri-Cyclen® + BMS-650032</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy Females, 18-40 years, BMI 18 - 32kg/m². Must use an acceptable method of
             contraception to avoid pregnancy throughout the study and 8 weeks after last dose of
             study drug

        Exclusion Criteria:

          -  Abnormal pap smear within 1 year prior to day 1

          -  Any significant or chronic uncontrolled medical illness
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pra International</name>
      <address>
        <city>Lenexa</city>
        <state>Kansas</state>
        <zip>66219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>For FDA Safety Alerts and Recalls refer to the following link: http://www.fda.gov/MEDWATCH/safety.htm</description>
  </link>
  <verification_date>June 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 3, 2010</study_first_submitted>
  <study_first_submitted_qc>February 3, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 5, 2010</study_first_posted>
  <last_update_submitted>January 24, 2011</last_update_submitted>
  <last_update_submitted_qc>January 24, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 25, 2011</last_update_posted>
  <responsible_party>
    <name_title>Study Director</name_title>
    <organization>Bristol-Myers Squibb</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Contraceptive Agents</mesh_term>
    <mesh_term>Norgestimate, ethinyl estradiol drug combination</mesh_term>
    <mesh_term>Contraceptives, Oral</mesh_term>
    <mesh_term>Moxifloxacin</mesh_term>
    <mesh_term>Fluoroquinolones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

